Integra LifeSciences (NASDAQ:IART) Stock Rating Lowered by JPMorgan Chase & Co.

Integra LifeSciences (NASDAQ:IART – Get Rating) was downgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Wednesday, The Fly reports. They currently have a $43.00 price target on the life sciences company’s stock, down from their prior price target of $56.00. JPMorgan Chase & Co.‘s target price indicates a potential upside of 11.75% from the stock’s previous close.

A number of other equities research analysts have also issued reports on IART. TheStreet lowered shares of Integra LifeSciences from a “b-” rating to a “c+” rating in a report on Monday. StockNews.com began coverage on shares of Integra LifeSciences in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. Citigroup lowered shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $59.00 to $39.00 in a research note on Tuesday. JMP Securities decreased their target price on shares of Integra LifeSciences from $75.00 to $65.00 in a research report on Thursday, April 27th. Finally, Truist Financial decreased their target price on shares of Integra LifeSciences from $58.00 to $54.00 in a research report on Thursday, May 18th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $51.14.

Integra LifeSciences Trading Down 1.7 %

Shares of NASDAQ:IART opened at $38.48 on Wednesday. The company has a 50 day moving average of $53.62 and a 200-day moving average of $55.03. The firm has a market cap of $3.15 billion, a P/E ratio of 18.68, a P/E/G ratio of 1.19 and a beta of 1.15. Integra LifeSciences has a twelve month low of $38.13 and a twelve month high of $62.99. The company has a current ratio of 3.65, a quick ratio of 2.40 and a debt-to-equity ratio of 0.86.

Integra LifeSciences (NASDAQ:IART – Get Rating) last issued its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.74. Integra LifeSciences had a net margin of 11.00% and a return on equity of 16.29%. The company had revenue of $380.85 million during the quarter, compared to analyst estimates of $373.21 million. During the same period in the prior year, the business posted $0.74 EPS. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. As a group, analysts anticipate that Integra LifeSciences will post 3.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Michael J. Mcbreen sold 1,843 shares of the company’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total transaction of $100,056.47. Following the completion of the sale, the executive vice president now directly owns 28,796 shares of the company’s stock, valued at approximately $1,563,334.84. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, EVP Michael J. Mcbreen sold 1,843 shares of the company’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total transaction of $100,056.47. Following the completion of the sale, the executive vice president now directly owns 28,796 shares of the company’s stock, valued at approximately $1,563,334.84. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Lisa Evoli sold 3,767 shares of the company’s stock in a transaction on Monday, February 27th. The shares were sold at an average price of $57.00, for a total transaction of $214,719.00. Following the transaction, the executive vice president now owns 18,605 shares of the company’s stock, valued at $1,060,485. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds have recently added to or reduced their stakes in the stock. Fifth Third Bancorp grew its holdings in Integra LifeSciences by 40.8% during the 4th quarter. Fifth Third Bancorp now owns 631 shares of the life sciences company’s stock worth $35,000 after acquiring an additional 183 shares during the last quarter. Ronald Blue Trust Inc. grew its holdings in Integra LifeSciences by 118.0% during the 4th quarter. Ronald Blue Trust Inc. now owns 641 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 347 shares during the last quarter. Neo Ivy Capital Management bought a new stake in Integra LifeSciences during the 3rd quarter worth about $30,000. Global Retirement Partners LLC boosted its stake in shares of Integra LifeSciences by 3,103.7% in the 1st quarter. Global Retirement Partners LLC now owns 865 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 838 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in shares of Integra LifeSciences by 595.7% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,294 shares of the life sciences company’s stock valued at $55,000 after purchasing an additional 1,108 shares during the last quarter. Institutional investors own 87.60% of the company’s stock.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.